Research and Clinical Trials

Gilead 1490
Brief Description  
This is a study for treatment-naïve HIV patients. This study is comparing the safety and efficacy of a new drug combination (GS-9883/FTC/TAF) to Dolutegravir + FTC/TAF. The trial is expected to last 2 years. The study sponsor will cover all cost related to the study including office visits, labs and medications.
Who may be Eligible  
Patients may be eligible if they meet the following: Adults (18 years or older); HIV positive with no history of therapy; Normal maintenance labs and EKG; Agree to not become pregnant or father a child during the study; Agree to birth control methods as outlined by the study protocol; have no new infections in the past month that required hospitalization or IV therapy; No history of cancer in the past 5 years; New acute hepatitis B is an exclusion; Active tuberculosis is an exclusion.
Start Date  
IRB Number  
Principal Investigator  
Johnson, Marc
Contact Name  

For More Information, Contact   Jessica  A.  Kearney-Bryan , BSN
Phone:  (704) 355-0244  Fax:  (704) 446-7641 
Address:  1350 S. Kings Drive, 3rd Floor Myer's Park ID Clinic
Charlotte, NC 28207